Research

Hormonal

Treating 50% of moderate- to high-risk obesity patients (Class II and III, excluding diabetes) with 2.4 mg weekly semaglutide plus lifestyle intervention for 68 weeks reduces population prevalence of these obesity classes and yields significant annual societal cost savings.

For healthcare policymakers and insurers, implementing widespread access to 2.4 mg weekly semaglutide for moderate-to-high risk obesity (excluding diabetics) alongside lifestyle programs can significantly reduce the prevalence of severe obesity and save billions in societal costs over time. This requires ensuring affordability and addressing long-term adherence.

ModerateSupportsMEDIUM confidence
Treating 50% of patients with obesity class II and III (excl. diabetes patients, including patients not responding to the treatment) over 68 weeks, reduced the prevalence from 4% to 2.74%... and from 1.45% to 0.97%... This resulted in a reduction of 12.9% (€ − 108.7 million) of expenses related to obesity class II and III per year.
Stephanie Reitzinger et al. · Scientific Reports · 2025

Why this rating

Based on a life-cycle model using data from a clinical trial (Wilding et al.) and population surveys; not a primary RCT itself.

Source

Effects from treating moderate- to high-risk obesity patients with anti-obesity medication from a societal perspective

Stephanie Reitzinger et al. · Scientific Reports · 2025

DOI 10.1038/s41598-025-97472-8

economic_model · n=15461Cited 1×
Read the paper
DOI resolved against Crossref · corpus check 2026-06-10

This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →